BioXgen Seeks Crowdfunding Investment for Cardiac Patch Targeting Post-Surgery Complication
BioXgen is launching a Regulation Crowdfunding investment round and hosting a webinar to demonstrate its cardiac patch designed to prevent postoperative atrial fibrillation, a common complication affecting nearly half of open-heart surgery patients.
BioXgen announced an open investment offering under Regulation Crowdfunding alongside a live investor webinar scheduled for April 30, 2026. The event will feature a demonstration of the company's cardiac patch on a heart model and presentations from leadership regarding development progress and regulatory milestones. The company is developing the patch to address postoperative atrial fibrillation, which affects nearly half of the more than 500,000 Americans who undergo open-heart surgery annually, representing the most common complication with no FDA-approved prevention device currently available.
Clinical data cited by BioXgen indicates the patch could achieve a tenfold reduction in postoperative AFib rates. The company reports the device is fully developed and that an FDA pre-submission has been filed, marking a significant step toward regulatory review. During the webinar, Dr. David Skinner and Dr. John Konhilas will present the device, explain its surgical application, discuss the clinical rationale, and answer live questions about both the technology and the investment opportunity.
"This is a chance for investors to see exactly what BioXgen has built and why we believe it could change the future of open-heart surgery," said Dr. David Skinner, President and CEO of BioXgen. "We have moved beyond concept. The device is finished, the regulatory process is underway, and we are excited to open this next phase of growth to the community." The investment round allows eligible investors to participate as the company advances toward FDA clearance and commercialization.
The webinar aims to provide a detailed look at the device, the clinical problem it addresses, and the market opportunity surrounding POAF prevention. Attendees can view the product, learn about company progress, and ask questions about the investment offering. To learn more about the offering, visit https://invest.bioxgen.life. To attend the webinar, registration is available at https://dnagency.lpages.co/bioxgen-device-reveal-and-investor-update/.
BioXgen has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained at https://invest.bioxgen.life/. The company's approach is built on 15 years of peer-reviewed research in biological scaffold technology and published clinical data showing reduced POAF incidence.